-
2024-512132-29-00
4
2025-08-06
Metastatic castration-resistant prostate cancer
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-518812-38-00
4
2025-07-02
Non-small cell lung cancer (NSCLC)
-
2024-513869-39-00
5
2025-06-27
Obstructive Cardiomyopathy, Hypertrophic
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-517458-90-00
5
2025-06-06
Chronic obstructive pulmonary disease (COPD)
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2024-517101-87-00
5
2025-05-26
Intestinal Malabsorption
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-517812-31-00
6
2025-05-21
Haemophilia A
-
2024-515984-68-00
4
2025-05-20
Non-small cell lung cancer (NSCLC)
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-517579-19-00
3
2025-03-24
Selected Advanced Solid Tumors
-
2024-513547-82-00
5
2025-03-11
Transthyretin Amyloidosis
-
2024-515034-33-00
9
2025-03-05
Mantle Cell Lymphoma
-
2023-505245-13-00
6
2025-02-12
Chronic obstructive pulmonary disease (COPD)
-
2024-512960-75-00
5
2025-02-04
Resectable Non-small cell lung cancer
-
2024-519825-39-00
4
2025-01-30
Locally advanced colon cancer (LACC)
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer